Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Oct. 29, 2014, 60 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $1,000.00 to $206,654,400.00.

Highlighted Stocks Traded by Insiders:

NPS Pharmaceuticals (NPSP) - FREE Research Report

Beshar Luke M, who is Evp & Cfo at NPS Pharmaceuticals, sold 30,635 shares at $26.75 on Oct. 29, 2014. Following this transaction, the Evp & Cfo owned 82,780 shares meaning that the stake was reduced by 27.01% with the 30,635-share transaction.

The shares most recently traded at $27.75, up $1.00, or 3.59% since the insider transaction. Historical insider transactions for NPS Pharmaceuticals go as follows:

  • 12-Week # shares sold: 129,658
  • 24-Week # shares sold: 129,658

The average volume for NPS Pharmaceuticals has been 2.3 million shares per day over the past 30 days. NPS Pharmaceuticals has a market cap of $3.0 billion and is part of the health care sector and drugs industry. Shares are down 10.38% year-to-date as of the close of trading on Wednesday.

NPS Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development of therapeutic products in the United States. Its lead product is Gattex for the treatment of adult patients with short bowel syndrome (SBS) who are dependent on parenteral support. The company has a P/E ratio of 703.0. Currently, there are 8 analysts who rate NPS Pharmaceuticals a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on NPSP - FREE

TheStreet Quant Ratings rates NPS Pharmaceuticals as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, impressive record of earnings per share growth and compelling growth in net income. However, as a counter to these strengths, we find that the stock has experienced relatively poor performance when compared with the S&P 500 during the past year. Get the full NPS Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Chubb (CB) - FREE Research Report

Robusto Dino, who is Executive Vice President at Chubb, sold 21,100 shares at $97.73 on Oct. 29, 2014. Following this transaction, the Executive Vice President owned 39,691 shares meaning that the stake was reduced by 34.71% with the 21,100-share transaction.

The shares most recently traded at $98.01, up $0.28, or 0.29% since the insider transaction. Historical insider transactions for Chubb go as follows:

  • 4-Week # shares sold: 1,000
  • 12-Week # shares sold: 1,000
  • 24-Week # shares sold: 13,140

The average volume for Chubb has been 1.1 million shares per day over the past 30 days. Chubb has a market cap of $23.6 billion and is part of the financial sector and insurance industry. Shares are up 1.25% year-to-date as of the close of trading on Wednesday.

The Chubb Corporation, through its subsidiaries, provides property and casualty insurance to businesses and individuals. The stock currently has a dividend yield of 2.04%. The company has a P/E ratio of 11.6. Currently, there are 3 analysts who rate Chubb a buy, 1 analyst rates it a sell, and 9 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CB - FREE

TheStreet Quant Ratings rates Chubb as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, impressive record of earnings per share growth and increase in net income. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Chubb Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Splunk (SPLK) - FREE Research Report

Neustaetter Thomas M, who is Director at Splunk, sold 6,500 shares at $65.70 on Oct. 29, 2014. Following this transaction, the Director owned 35,564 shares meaning that the stake was reduced by 15.45% with the 6,500-share transaction.

The shares most recently traded at $64.40, down $1.30, or 2.01% since the insider transaction. Historical insider transactions for Splunk go as follows:

  • 4-Week # shares sold: 41,666
  • 12-Week # shares sold: 119,259
  • 24-Week # shares sold: 171,296

The average volume for Splunk has been 3.0 million shares per day over the past 30 days. Splunk has a market cap of $8.0 billion and is part of the technology sector and computer software & services industry. Shares are down 6.54% year-to-date as of the close of trading on Wednesday.

Splunk, Inc. provides software solutions that provide real-time operational intelligence in the United States and internationally. Currently, there are 15 analysts who rate Splunk a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on SPLK - FREE

TheStreet Quant Ratings rates Splunk as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, generally disappointing historical performance in the stock itself and feeble growth in its earnings per share. Get the full Splunk Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null